High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma

被引:20
作者
Chen, J [1 ]
Balthasar, JP [1 ]
机构
[1] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2005年 / 816卷 / 1-2期
关键词
topotecan; anti-TPT antibodies; HPLC;
D O I
10.1016/j.jchromb.2004.11.035
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A rapid and sensitive high-performance liquid chromatographic (HPLC) assay has been developed to allow determination of total (i.e. bound and unbound) and free (i.e. unbound) topotecan (TPT) in mouse plasma in the presence and absence of anti-TPT antibodies. The chromatographic analysis was carried out using reversed-phase isocratic elution with a Nova-Pak C18 column (3.9 mm x 150 min, 4 mum) protected by a Nova-Pak C18 guard column (3.9 nun x 20 mm, 4 mum), where 10 mM KH2PO4-methanol-triethylamine (72:26:2 (v/v/v), pH 3.5) was used as the mobile phase. Topotecan was quantified with fluorescence detection using an excitation wavelength of 361 nm and an emission wavelength of 527 nm. The retention time for the internal standard, acridine, and TPT were 7.4 and 9.0 min, respectively. The lower limit of quantitation (LOQ) for TPT was determined as 0.02 ng in mouse plasma and mouse plasma ultrafiltrate, corresponding to a concentration of 1 ng/ml in 20 mul mouse plasma. The assay was shown to be linear over a concentration range of 1-500 ng/ml. The recoveries of free and total TPT from spiked mouse plasma were within 10% of theoretical values (assessed at 1, 20 and 500 ng/ml). The validated HPLC assay was applied to evaluate TPT pharmacokinetics following administration of TPT to Swiss Webster mice and to hyperimmunized and control BALB/c mice. The assay has been shown to be capable for measuring total and free TPT in mouse plasma with high sensitivity and will allow the testing of the effect of anti-TPT antibodies on the disposition of TPT. (C) 2004 Elsevier B.V All rights reserved.
引用
收藏
页码:183 / 192
页数:10
相关论文
共 28 条
[1]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[2]  
[Anonymous], 2001, EUR J CANCER, DOI DOI 10.1016/S0959-8049(01)00328-8
[3]   Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection [J].
Bai, F ;
Kirstein, MN ;
Hanna, SK ;
Iacono, LC ;
Johnston, B ;
Stewart, CF .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 784 (02) :225-232
[4]  
BALTHASAR J, 1994, J PHARMACOL EXP THER, V268, P734
[5]   Inverse targeting of peritoneal tumors: Selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments [J].
Balthasar, JP ;
Fung, HL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (10) :1035-1043
[6]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF THE NEW ANTITUMOR DRUG SK-AND-F 104864-A (NSC 609699) IN PLASMA [J].
BEIJNEN, JH ;
SMITH, BR ;
KEIJER, WJ ;
VANGIJN, R ;
HUININK, WWT ;
VLASVELD, LT ;
RODENHUIS, S ;
UNDERBERG, WJM .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1990, 8 (8-12) :789-794
[7]   Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts [J].
De Cesare, M ;
Zunino, F ;
Pace, S ;
Pisano, C ;
Pratesi, G .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (12) :1558-1564
[8]  
DEDRICK RL, 1978, CANCER TREAT REP, V62, P1
[9]  
GROCHOW LB, 1992, DRUG METAB DISPOS, V20, P706
[10]   Clinical pharmacokinetics of topotecan [J].
Herben, VMM ;
Huinink, WWTB ;
Beijnen, JH .
CLINICAL PHARMACOKINETICS, 1996, 31 (02) :85-102